8-K: China Pharma Acquires Ipragliflozin Patent for $9.8M in Stock

China Pharma Holdings, Inc. subsidiary Helpson acquired an invention patent for Ipragliflozin tablets for $9.8 million, paid in common stock.

Summary

• Hainan Helpson Medical & Biotechnology Co., Ltd (Helpson), a wholly-owned subsidiary of China Pharma Holdings, Inc., entered into a Technology Transfer Agreement with Juan Zhang on December 22, 2025.
• Juan Zhang will transfer the ownership of an invention patent for "Ipragliflozin tablets and Method for Its Preparation" to Helpson.
• The transfer price is $9.8 million, which will be paid in common stock of the Company at $1.40 per share.
• This transaction involves the issuance of an aggregate of 7,000,000 restricted shares of common stock.
• The Transferor or a designated third party will provide technical services, including product research and development, writing registration materials, and registration application.
• The shares will be issued in reliance on the exemption from registration under Regulation S, as the recipient is a non-U.S. person and the transaction was negotiated and consummated offshore.

Sentiment

Score: 7

Explanation: The acquisition of a new patent for a known drug class (Ipragliflozin) represents a positive strategic move for product pipeline expansion, despite the dilution from stock issuance.

Positives

• Acquisition of an invention patent for Ipragliflozin tablets, a potential new product for the company's pipeline.
• The patent includes the method for preparation, providing comprehensive intellectual property for the drug.
• The agreement includes provisions for technical services covering product research, development, and registration, which can streamline the commercialization process.

Negatives

• The issuance of 7,000,000 restricted common shares will result in dilution for existing shareholders.
• Payment in stock rather than cash could suggest a strategic decision to preserve cash or potential liquidity considerations.

Risks

• The 7,000,000 shares issued are restricted and not registered under the Securities Act, relying on Regulation S, which may affect their future liquidity or transferability.
• Future dilution of existing shareholders due to the issuance of new common stock.
• The successful commercialization of Ipragliflozin tablets is contingent on future research, development, and successful regulatory registration, which carries inherent risks.

Future Outlook

The company anticipates engaging in product research and development, preparing registration materials, and applying for registration for the Ipragliflozin tablets, indicating a strategic move towards expanding its product pipeline and potential market offerings.

Management Comments

• The registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. (Signed by Zhilin Li, President and Chief Executive Officer)

Industry Context

The acquisition of an Ipragliflozin patent positions China Pharma Holdings to potentially enter or expand its presence in the diabetes treatment market, a significant and growing segment within the pharmaceutical industry. Ipragliflozin is an SGLT2 inhibitor, a class of drugs used to treat type 2 diabetes.

Stakeholder Impact

• Shareholders: Experience dilution due to the issuance of 7,000,000 new common shares.
• Company: Gains a new invention patent, potentially expanding its product portfolio and future revenue streams.
• Customers: Potential for a new treatment option (Ipragliflozin tablets) in the future.

Next Steps

• Product research and development for Ipragliflozin tablets.
• Writing of registration materials for the new product.
• Registration application for Ipragliflozin tablets.

Key Dates

Recommendation

The acquisition of a new patent for Ipragliflozin tablets is a strategic positive, indicating potential for future product development and market expansion. However, the significant equity issuance of 7,000,000 shares, representing a $9.8 million payment, will dilute existing shareholders. The long-term success depends on successful R&D and regulatory approval, introducing future execution risk. Given the balance of strategic growth and immediate dilution, a "hold" recommendation is appropriate, awaiting further clarity on product development and market penetration.

Keywords

China Pharma Holdings, CPHI, Ipragliflozin, Technology Transfer, Patent Acquisition, Pharmaceuticals, Drug Development, Equity Issuance, Regulation S, Hainan Helpson